Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$208M |
| 2 |
Lowe's Companies
LOW
|
+$198M |
| 3 |
American Tower
AMT
|
+$161M |
| 4 |
Lennar Class A
LEN
|
+$150M |
| 5 |
British American Tobacco
BTI
|
+$150M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$208M |
| 2 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$177M |
| 3 |
Crown Castle
CCI
|
+$168M |
| 4 |
Walmart Inc
WMT
|
+$167M |
| 5 |
Entergy
ETR
|
+$157M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 13.75% |
| 2 | Technology | 13.18% |
| 3 | Healthcare | 11.51% |
| 4 | Industrials | 10.45% |
| 5 | Consumer Discretionary | 9.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
PUT
Glaukos
GKOS
$10.7B
| $970K | ﹤0.01% |
+29,400
| New | +$1.12M |
|
2527
Summit Therapeutics
SMMT
$10.7B
| $968K | ﹤0.01% |
77,114
+1,291
| +2% | +$16.7K |
|
2528
Badger Meter
BMI
$3.95B
| $967K | ﹤0.01% |
+19,730
| New | +$877K |
|
2529
Vanguard Morningstar Value ETF
VTV
$194B
| $966K | ﹤0.01% |
9,678
-15,917
| -62% | -$1.56M |
|
|
NP
2530
DELISTED
Neenah, Inc. Common Stock
NP
| $966K | ﹤0.01% |
+11,287
| New | +$894K |
|
|
LRFC
2531
DELISTED
Logan Ridge Finance Corp
LRFC
| $964K | ﹤0.01% |
16,843
-635
| -4% | -$41K |
|
|
SIOX
2532
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $963K | ﹤0.01% |
+17,500
| New | +$2.95M |
|
|
CACQ
2533
DELISTED
Caesars Acquisition Company
CACQ
| $963K | ﹤0.01% |
+44,900
| New | +$868K |
|
2534
Coherus Oncology
CHRS
$212M
| $962K | ﹤0.01% |
72,038
+42,693
| +145% | +$565K |
|
2535
Reaves Utility Income Fund
UTG
$3.52B
| $962K | ﹤0.01% |
30,332
+15,317
| +102% | +$532K |
|
2536
Wave Life Sciences
WVE
$1.03B
| $962K | ﹤0.01% |
44,241
-27,948
| -39% | -$562K |
|
2537
CALL
Regenxbio
RGNX
$588M
| $959K | ﹤0.01% |
+29,100
| New | +$655K |
|
|
PZN
2538
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $958K | ﹤0.01% |
87,947
-50,088
| -36% | -$512K |
|
2539
Rush Enterprises Class B
RUSHB
$8.44B
| $957K | ﹤0.01% |
49,370
+29,428
| +148% | +$498K |
|
2540
World Kinect Corp
WKC
$1.81B
| $957K | ﹤0.01% |
28,220
+21,779
| +338% | +$777K |
|
|
MRSN
2541
DELISTED
Mersana Therapeutics
MRSN
| $955K | ﹤0.01% |
2,210
-231
| -9% | -$91K |
|
|
BFYT
2542
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $953K | ﹤0.01% |
65,745
-109,253
| -62% | -$3.02M |
|
2543
CALL
Inogen
INGN
$147M
| $951K | ﹤0.01% |
+10,000
| New | +$964K |
|
2544
Valhi
VHI
$509M
| $951K | ﹤0.01% |
32,618
-13,951
| -30% | -$448K |
|
|
RYZ
2545
Ryerson Holding Corp
RYZ
$1.28B
| $949K | ﹤0.01% |
+87,436
| New | +$771K |
|
2546
Invesco DB US Dollar Index Bullish Fund
UUP
$321M
| $949K | ﹤0.01% |
39,227
-160,773
| -80% | -$3.89M |
|
|
BEL
2547
DELISTED
Belmond Ltd.
BEL
| $947K | ﹤0.01% |
69,364
-21,489
| -24% | -$276K |
|
2548
Axsome Therapeutics
AXSM
$10.8B
| $944K | ﹤0.01% |
170,058
+10,098
| +6% | +$54.2K |
|
2549
Schwab US Broad Market ETF
SCHB
$44.6B
| $942K | ﹤0.01% |
92,772
+31,044
| +50% | +$308K |
|
2550
Nice
NICE
$5.88B
| $940K | ﹤0.01% |
+11,555
| New | +$898K |
|
Similar funds
Israel Englander's Q3 2017 Portfolio in Review
As of Q3 2017, Israel Englander held 4,198 positions worth $65.6B, up 17% from $56.1B the previous quarter. Its ten largest holdings account for 7.8% of the portfolio.
Israel Englander deployed $6.37B of net new capital in Q3 2017, opening 794 new positions and adding to 1,441 existing holdings. Its largest new stake was Northern Trust: 1,591,041 shares worth $146M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Gilead Sciences, an estimated $208M trimmed.
- Israel Englander's largest Q3 2017 buy was Northern Trust: 1,591,041 shares worth $146M.
- Israel Englander added most to Salesforce in Q3 2017, an estimated $208M increase.
- Israel Englander's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $208M.
- Israel Englander fully exited CONCHO RESOURCES INC. in Q3 2017, selling an estimated $177M.
- Israel Englander's ten largest holdings make up 7.8% of its $65.6B portfolio in Q3 2017.
- Israel Englander opened 794 new positions and closed 737 in Q3 2017.
- Israel Englander's portfolio value rose 17% quarter-over-quarter to $65.6B.
Based on Millennium Management's 13F filing for Q3 2017, filed 14 Nov 2017.